Liposomal Drug Delivery Devices Market Report 2025

The liposomal drug delivery devices market size has grown rapidly in recent years. It will grow from $4.89 billion in 2024 to $5.38 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to drug delivery advancements, biomedical research, clinical validation, therapeutic applications, and biocompatibility enhancements.

The liposomal drug delivery devices market size is expected to see rapid growth in the next few years. It will grow to $8.61 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to targeted therapies expansion, clinical validation and trials, personalized medicine emphasis, combination therapies development, regulatory landscape changes. Major trends in the forecast period include biocompatible liposomal materials, innovations in delivery systems, application in oncology, combination therapies, customized liposome formulations.

The increasing number of cancer cases worldwide is expected to drive the growth of the liposomal drug delivery devices market during the forecast period. Liposomal drug delivery systems are employed as targeted therapies for cancer treatments, including radiation therapy, chemotherapy, and surgical resection. For instance, data published by Macmillan Cancer Support, a UK-based cancer charity, in June 2022, indicated that the number of individuals living with cancer reached 3 million in 2022 and is projected to rise to nearly 3.5 million by 2025 and 4 million by 2030 in the UK. Thus, the global increase in cancer incidence is anticipated to enhance the demand for liposomal drug delivery devices in the coming years.

Rising healthcare expenditure is expected to accelerate the growth of the liposomal drug delivery devices market in the future. This increase in healthcare spending can be attributed to several interconnected factors, including the growing prevalence of chronic diseases, advancements in medical technology, rising drug prices, consumer expectations, and insurance costs. Healthcare expenditure includes a wide range of medical and healthcare-related costs, encompassing expenses associated with liposomal drug delivery devices. These expenditures cover various facets of healthcare, including the research, development, manufacturing, distribution, and utilization of medical technologies and devices like liposomal drug delivery systems. For example, a report from the Peter G Foundation, a US-based consulting firm, in July 2022, projected that both public and private healthcare spending would rise from $4.4 trillion, or $13,413 per person, in 2022 to $7.2 trillion, or $20,425 per person, by 2031. In relation to GDP, National Healthcare Expenditure (NHE) is expected to increase from 17.4% in 2022 to approximately 20% by 2031, as healthcare costs escalate faster than economic growth. Therefore, the rising healthcare expenditure is driving the growth of the liposomal drug delivery devices market.

Numerous large companies are implementing various strategic initiatives, including new product development, which is expected to become a significant trend in the liposomal drug delivery devices market. These companies are collaborating to create liposomal drug delivery systems to enhance their product portfolios and expand their global operations. For example, in May 2024, Insmed, Inc., a US-based biotech firm, announced data from the ARISE study regarding ARIKAYCE (amikacin liposome inhalation suspension). Patients treated with ARIKAYCE demonstrated better outcomes than those receiving the comparator arm (a macrolide-based multi-drug regimen), as measured by the QOL-B instrument, with 43.8% of patients showing an improvement in their QOL-B respiratory score.

Key players in the liposomal drug delivery market are launching innovative products like liposomal nanostructures to gain a competitive advantage. Researchers have been focused on developing these nanostructures to enhance patient compliance by allowing for less frequent dosing while maintaining effectiveness. For instance, in February 2022, the National Center for Biotechnology Information reported that several commercial nano-liposomal products, such as Onivyde, Vyxeos, and Marqibo, have been approved and are currently utilized. These medications are specifically used in cancer treatment for certain types of leukemia or solid tumors, playing a vital role in oncology by providing therapeutic options for cancers that may resist conventional chemotherapy or necessitate liposomal drug delivery.

Leading companies in the liposomal drug delivery market are introducing groundbreaking products such as hydrochloride liposome injection to establish a competitive edge. Researchers are focused on creating liposomal nanostructures that improve patient compliance by enabling less frequent dosing while ensuring efficacy. For instance, in August 2024, Lupin Ltd., an India-based pharmaceutical company, launched Doxorubicin Hydrochloride Liposome Injection in two formulations: 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL). As of June 2024, this injection had an estimated annual sales figure of approximately USD 40.9 million in the U.S. market. This positions Lupin strategically within the oncology segment, expanding its portfolio to include this significant cancer treatment option. Lupin's commitment to enhancing patient health outcomes is reflected in this launch, as it aims to provide effective treatment alternatives in a competitive pharmaceutical landscape.

Major companies operating in the liposomal drug delivery devices market include Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., CSPC Pharmaceutical Group Limited, Ipsen SA, Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co. Ltd., Nanomerics Ltd., Luye Pharma Group Ltd., Leadiant Biosciences Inc., Pacira Biosciences Inc., Nippon Kayaku Co. Ltd., Celsion Corporation, Acrotech Biopharma Inc., Aphios Pharma LLC, CytImmune Sciences Inc., NanoSphere Health Sciences Inc., Cel-Sci Corporation, Lipoid GmbH, Liposome Company Inc., Liposome Research Days Corporation, Taiwan Liposome Company, T&T Scientific Corporation.

North America was the largest region in the liposomal drug delivery devices market in 2024. Asia-Pacific was the second-largest region in the global liposomal drug delivery devices market share. The regions covered in the liposomal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liposomal drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Liposomal drug delivery devices are microscopic colloidal spheres utilized to transport drug molecules to specific action sites.

Primary types encompass liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. Liposomal doxorubicin, a chemotherapy drug under the anthracycline category, encapsulated within a liposome, inhibits cancer cell growth by blocking the enzyme topoisomerase. These devices find applications in treating fungal diseases, cancer therapy, pain management, viral vaccines, and photodynamic therapy, utilized in hospitals, diagnostic centers, ambulatory surgery centers/clinics, and similar medical settings.

The liposomal drug delivery devices market research report is one of a series of new reports that provides liposomal drug delivery devices market statistics, including liposomal drug delivery devices industry global market size, regional shares, competitors with a liposomal drug delivery devices market share, detailed liposomal drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the liposomal drug delivery devices industry. This liposomal drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liposomal drug delivery devices market consists of sales of instruments such as liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.